Crispr Therapeutics is trading 4.1% up at $51.59 after reporting second-quarter results that beat revenue and EPS expectations, driven by rapid CASGEVY launch momentum.
- CASGEVY sales jumped 151% year-over-year to $76 million, representing 78% sequential growth.
- The FDA expanded the treatment's label to include children as young as 2, significantly enlarging the eligible patient pool.
- The move is also supported by a broader biotech rally and strong overall market sentiment.